Skip to content
OpenCapital
Get started

Organon OGN Nasonex — Revenue

Other product segments

Nexplanon/Implanon NXT
$201M-19.0%
Other
$87M+11.5%
Zetia
$87M+2.4%
Atozet
$85M+10.4%
Other Non-Opiod Pain, Bone and Dermatology
$68M0.0%
Hadlima
$67M+42.6%
Follistim AQ
$61M-11.6%
Arcoxia
$59M-4.8%
Cozaar/Hyzaar
$57M+3.6%
Renflexis
$57M0.0%
Emgality
$54M+68.8%
Other Women's Health
$46M+7.0%
Singulair
$40M-45.9%
Diprospan
$35M+16.7%
Dulera
$35M-18.6%
Clarinex
$31M-8.8%
Propecia
$30M+15.4%
Fosamax
$29M-12.1%
Other Cardiovascular
$28M-6.7%
Ganirelix Acetate Injection
$26M-3.7%
Marvelon/Mercilon
$26M-33.3%
Proscar
$26M+8.3%
Vtama
$25M+4.2%
NuvaRing
$24M+9.1%
Other Biosimilars
$24M—
Vytorin
$21M-8.7%
Brenzys
$20M+42.9%
Other Respiratory
$12M-7.7%
Rosuzet
$6M+50.0%
Jada
$5M-66.7%
Ontruzant
$5M-72.2%

Similar metrics at other companies

Amneal Pharmaceuticals, Inc. logo
AMRXHormonal / allergy — Net revenue
$35.93M+5.1%
Incyte logo
INCYNet sales — Total revenues
$1.1B+19.8%
Bristol-Myers Squibb logo
BMYNet product sales — Total Revenues
$11.17B+2.6%
Regeneron Pharmaceuticals logo
REGNLynozyfic — Revenue
$11.2M—
Neurocrine Biosciences logo
NBIXNet product sales — Total revenues
$811M+43.9%
Viatris logo
VTRSDymista ® — Net Sales
$37.3M-12.9%

Other financials

Income statement

See full
Revenue$1.5B-3.5%
Gross profit$783.0M-6.9%
Net income$146.0M+67.8%
EPS (diluted)$0.55+66.7%

Balance sheet

See full
Cash & equivalents$1.1B+104%
Total debt$8.6B-4.3%
Total equity$903.0M+66.6%
Total assets$13.0B-1.2%

Cash flow

See full
Operating cash flow$225.0M+200%
CapEx$37.0M+15.6%
Free cash flow$188.0M+337%

Valuation

See full
Market cap$3.53B-59.4%

Profitability

See full
Gross margin52.8%-4.4pp
Net margin8%-12.3pp
FCF margin11.1%-1.3pp

Returns & leverage

See full
Return on equity71.6%—
Debt / equity9.5×-7.0×
Current ratio2×+0.3×

Where this comes from

Reported directly by Organon in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Organon’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Organon's nasonex — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Organon's nasonex — revenue?
Organon (OGN) reported nasonex — revenue of $65M in Q1 2026.
How has Organon's nasonex — revenue changed year-over-year?
Organon's nasonex — revenue decreased by 9.7% year-over-year, from $72M to $65M.
What is the long-term trend for Organon's nasonex — revenue?
Over 4 years (2021 to 2025), Organon's nasonex — revenue has grown at a 6.4% compound annual growth rate (CAGR), from $205M to $263M.
What does nasonex — revenue mean?
This metric represents the total gross revenue generated from the sale of the Nasonex product line within the established medicines portfolio. It reflects the market demand and commercial performance of this specific respiratory therapeutic asset. Monitoring these revenues helps investors assess the lifecycle maturity and revenue contribution of legacy pharmaceutical brands within the company's broader product mix.